Author

D. G. Rees

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:protein folding & dynamics· 1

Frequent Co-Authors

A. Buchanan· 1 shared B. P. Kemp· 1 shared B. Popovic· 1 shared C. Colley· 1 shared C. E. C. Huntington· 1 shared C. Hollins· 1 shared D. A. Sims· 1 shared D. C. Lowe· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Buchanan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

E. England, D. G. Rees, I. C. Scott, S. Carmen, D. T. Y. Chan, C. E. C. Huntington, K. F. Houslay, T. Erngren, M. Penney, J. B. Majithiya, L. Rapley, D. A. Sims, C. Hollins, E. C. Hinchy, M. D. Strain, , E. S. Cohen

This paper describes tozorakimab, an anti-IL-33 antibody that inhibits both reduced and oxidized IL-33 signaling pathways to reduce inflammation and epithelial dysfunction.

bioRxiv · Feb 28, 2023Immunology

In vitro Evolution of Antibody Affinity via Insertional Mutagenesis Scanning of an Entire Antibody Variable Region

K. Skamaki, S. Emond, M. Chodorge, J. Andrews, D. G. Rees, D. Cannon, B. Popovic, A. Buchanan, R. Minter, F. Hollfelder

This paper demonstrates that insertional mutagenesis can enhance antibody affinity, achieving a 256-fold improvement in an anti-IL-13 antibody through InDel mutagenesis combined with point mutations.

bioRxiv · Apr 26, 2020Biochemistry